| Cholesteryl ester transfer protein (CETP) genotype and reduced CETP levels associated with decreased prevalence of hypertension. | |
| | |
MedLine Citation:
|
PMID: 20511482 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: To clarify whether reduced cholesteryl ester transfer protein (CETP) activity carries inherent blood pressure risks and to infer whether the increased blood pressure and elevated mortality associated with torcetrapib are idiosyncratic or characteristic of this class of drugs. PATIENTS AND METHODS: We examined the associations among CETP genotype, phenotype, and blood pressure in a cohort of 521 older adults (who have complete data for the variables required in our primary analysis) enrolled between November 1, 1998, and June 30, 2003, in our ongoing studies of genes associated with longevity, including a cohort with a high prevalence of a genotype coding for a reduced activity variant of CETP and low levels of CETP. RESULTS: The prevalence of hypertension was actually lower among homozygotes for the variant CETP (48% vs 60% among those with wild-type and 65% among heterozygotes; P=.03). Low levels of CETP were associated with reduced prevalence of hypertension (65% in highest tertile, 59% in middle tertile, and 55% in lowest tertile; P=.04) and lower systolic blood pressure (140.8, 138.1, 136.2 mm Hg, respectively; P=.03). CONCLUSION: Reduced levels of CETP are associated with lower, not higher, blood pressure. The adverse results with torcetrapib, if mediated through blood pressure, are likely to represent effects of this specific drug, rather than a result of lower CETP levels. |
| | |
Authors:
|
Clyde B Schechter; Nir Barzilai; Jill P Crandall; Gil Atzmon |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural |
Journal Detail:
|
Title: Mayo Clinic proceedings. Mayo Clinic Volume: 85 ISSN: 1942-5546 ISO Abbreviation: Mayo Clin. Proc. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-31 Completed Date: 2010-06-18 Revised Date: 2011-03-03 |
Medline Journal Info:
|
Nlm Unique ID: 0405543 Medline TA: Mayo Clin Proc Country: United States |
Other Details:
|
Languages: eng Pagination: 522-6 Citation Subset: AIM; IM |
Affiliation:
|
Department of Family and Social Medicine, Albert Einstein College of Medicine, Bronx, NY, 10461, USA. clyde.schechter@Einstein.y.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Anticholesteremic Agents / adverse effects Blood Pressure Cholesterol Ester Transfer Proteins / blood*, genetics* Female Genotype Heterozygote Homozygote Humans Hypertension / epidemiology* Male Prevalence Quinolines / adverse effects |
| Grant Support | |
ID/Acronym/Agency:
|
AG027734/AG/NIA NIH HHS; AG18728/AG/NIA NIH HHS; DK20541/DK/NIDDK NIH HHS; M01-RR12248/RR/NCRR NIH HHS; RR12248/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Cholesterol Ester Transfer Proteins; 0/Quinolines; 262352-17-0/torcetrapib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized co...
Next Document: Opsoclonus-myoclonus syndrome in patients with locked-in syndrome: a therapeutic porthole with gabap...